Boston Therapeutics Announces Strategic Acquisition of CureDM

New Peptide Therapeutic adds to Pipeline of Novel Approaches to Diabetes

Manchester, New Hampshire, UNITED STATES

LAWRENCE, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (Boston Therapeutics) announces the acquisition of CureDM Group Holdings, LLC (CureDM), adding a Phase 2-ready drug to their portfolio.  The CureDM islet-growing peptide, HIP2B, has demonstrated clinical efficacy for type 2 diabetes by improving first phase insulin release, increasing fasting insulin levels and insulin secretion rates. Boston Therapeutics is committed to development of treatments that impact endogenous glucose regulation. This bold move to acquire the worldwide exclusive rights to commercialize HIP2B, alongside current product offerings, is a key part of the long term plan to alleviate the health, economic and quality of life burden of diabetes.

CureDM members contributed their membership interests for restricted shares of Boston Therapeutics to place their compound into the Boston Therapeutics portfolio of other technologies targeted for treatment of metabolic diseases (diabetes) and related complications.  Terms include milestones and addition of a CureDM designated board member to the board of Boston Therapeutics. 

“We are establishing our company and its alliance partners in Asia as one that is changing the way diabetes is treated,” says Carl W. Rausch, CEO of Boston Therapeutics.  He elaborates that, “Instead of a disease which you have to self-medicate for the rest of your life, we believe diabetes is a disease that can be either reversed or may be prevented entirely if you are pre-diabetic.  The HIP2B peptide is a game changing compound that will fit strategically into our portfolio.” CEO of CureDM, Loraine V. Upham, notes, “We are very excited to be joining forces with Boston Therapeutics and look forward to leveraging the many synergies that exist between us to advance all products to partnering and worldwide commercialization.”

Recent reporting from the American Diabetes Association celebrates strides in 2017 in diabetes management and improved outcomes that include better accessibility to continuous glucose monitors.  This technology is key to enabling patients to self-monitor their response to their patient centric treatments like BTI320 and HIP2B.  Management believes both treatments have the potential to change the way prediabetes and diabetes are managed and this may work independently or synergistically to improve long-term outcomes.

About Boston Therapeutics, Inc.
Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) is an innovator in design, development and commercialization of compounds, such as investigational BTI-320, to treat diabetes and diabetes related complications. SUGARDOWN is a registered trademark of Boston Therapeutics, Inc.

About CureDM Group Holdings, LLC,
CureDM Group Holdings, LLC, headquartered in Wilmington, DE with an office in Albuquerque, NM, was established in 2010 to execute clinical development of the novel peptide therapeutic, HIP2B, for the treatment of type 1 and type 2 diabetes.   

Forward Looking Statement
This press release includes forward-looking statements. These statements may be identified by words such as "feel," "believes," expects," "estimates," "projects," "intends," "should," "is to be," or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: our limited operations and need to expand in the near future; risks associated with obtaining regulatory approval of our products; the ability to protect our intellectual property; the potential lack of market acceptance of our products; potential competition; our inability to retain key members of our management team; our inability to raise additional capital to fund our operations and business plan; our ability to continue as a going concern; our liquidity and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission ("SEC"), including our annual report on Form 10-K filed with the SEC. Boston Therapeutics expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

Contact Data